News headlines about ConforMIS (NASDAQ:CFMS) have trended somewhat positive on Monday, according to Accern. The research firm identifies negative and positive news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. ConforMIS earned a media sentiment score of 0.09 on Accern’s scale. Accern also gave media stories about the medical instruments supplier an impact score of 44.5380514132231 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

ConforMIS (NASDAQ:CFMS) last announced its quarterly earnings results on Thursday, August 3rd. The medical instruments supplier reported ($0.28) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.36) by $0.08. The company had revenue of $18.50 million during the quarter, compared to the consensus estimate of $19.34 million. ConforMIS had a negative return on equity of 66.61% and a negative net margin of 72.87%. ConforMIS’s revenue for the quarter was down 4.1% on a year-over-year basis. During the same period in the previous year, the business earned ($0.34) EPS.

Several equities analysts have commented on the company. BTIG Research assumed coverage on ConforMIS in a research report on Tuesday, June 20th. They issued a “neutral” rating on the stock. Oppenheimer Holdings, Inc. reaffirmed a “buy” rating on shares of ConforMIS in a research report on Tuesday, June 20th. Zacks Investment Research downgraded ConforMIS from a “hold” rating to a “sell” rating in a research report on Tuesday, July 11th. Deutsche Bank AG reaffirmed a “hold” rating and issued a $5.00 price objective (down previously from $6.00) on shares of ConforMIS in a research report on Friday, August 4th. Finally, Canaccord Genuity cut their price objective on ConforMIS from $8.00 to $6.00 and set a “hold” rating on the stock in a research report on Friday, August 4th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and three have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $6.71.

ILLEGAL ACTIVITY WARNING: This news story was reported by Daily Political and is the sole property of of Daily Political. If you are viewing this news story on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this news story can be accessed at https://www.dailypolitical.com/2017/09/25/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-conformis-cfms-stock-price.html.

ConforMIS Company Profile

ConforMIS, Inc is a medical technology company. The Company uses its iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants, which are individually sized and shaped, to fit each patient’s anatomy. The Company’s iFit technology platform is applicable to various joints.

Insider Buying and Selling by Quarter for ConforMIS (NASDAQ:CFMS)

Receive News & Ratings for ConforMIS Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConforMIS Inc. and related companies with MarketBeat.com's FREE daily email newsletter.